Mazdutide is a once-weekly injection that acts on GLP-1 and glucagon receptors, developed by Innovent Biologics with Eli Lilly. It was approved in China in June 2025 as Xinermei for weight management and is not FDA approved.
Also known as: Xinermei.
There is no FDA-approved mazdutide product. Powder vials are usually labeled 5 mg or 10 mg.
Water and syringe-unit charts by vial size: 5 mg · 10 mg
Here is the math for a 10 mg vial mixed with 2 mL of bacteriostatic water, drawing 4 mg with a U-100 insulin syringe (1 mL = 100 units).
10 mg ÷ 2 mL = 5 mg/mL4 mg ÷ 5 mg/mL = 0.8 mL0.8 mL × 100 = 80 units| Amount | Volume | U-100 syringe |
|---|---|---|
| 2 mg | 0.4 mL | 40 units |
| 4 mg | 0.8 mL | 80 units |
| 8 mg | 1.6 mL | 160 units (over 1 mL) |
Adding more water doesn't change how much mazdutide is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 1 mL | 10 mg/mL | 0.4 mL | 40 units |
| 2 mL | 5 mg/mL | 0.8 mL | 80 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
In the phase 3 GLORY-1 trial (Ji, NEJM 2025; 610 adults in China with overweight or obesity, 48 weeks), people took 4 mg or 6 mg once weekly or placebo. Mean weight change at week 48 was −11.0% on 4 mg and −14.0% on 6 mg, versus +0.3% on placebo. Side effects were mostly gastrointestinal and mild to moderate.
The GLORY-2 trial (JAMA 2026) tested a higher 9 mg dose in Chinese adults with obesity. In June 2025 China approved mazdutide for long-term weight management, and in September 2025 for blood-sugar control in type 2 diabetes.
We could not open a primary human pharmacokinetic paper for mazdutide, so we do not list a half-life or time to peak here.